Post‐stem cell transplant maintenance in FLT3<sup>mut</sup> acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib-Reference-Cited by-同舟云学术

Post‐stem cell transplant maintenance in FLT3^mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib

Published:2024-04 Issue:2 Volume:5 Page:423-427
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Ashouri Karam¹^ORCID,Chennapan Krithika¹^ORCID,Martynova Anastasia¹,Nazaretyan Samvel¹,Ali Amir²,Ginosyan Anush Aram¹,Tam Eric²,Ladha Abdullah²,Woan Karrune²,Chaudhary Preet²,Siddiqi Imran³,Yaghmour George²^ORCID

Affiliation:

1. University of Southern California Keck School of Medicine Los Angeles California USA

2. Internal Medicine Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases University of Southern California Norris Comprehensive Cancer Center Los Angeles California USA

3. Department of Pathology University of Southern California Keck School of Medicine Los Angeles California USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.885

Reference10 articles.

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection

2. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies

3. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation

4. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML

5. BMT‐CTN 1506 (MORPHO): a randomized trial of the FLT3 inhibitor gilteritinib as post‐transplant maintenance for FLT3‐ITD AML;Levis MJ;Hemasphere,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: Post‐stem cell transplant maintenance in FLT3^mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib;eJHaem;2024-05-31